NCT02311569 2019-05-15
Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation
Swiss Cancer Institute
Phase 2 Completed
Clinical Trials
3 trialsNCT00750620 2013-09-05
A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment
Astellas Pharma Inc
Phase 1 Completed
NCT01579461 2013-09-05
A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects
Astellas Pharma Inc
Phase 1 Completed